Malignant craniopharyngiomas: Institutional experience and literature review
Brain Pathology · 2026
DOI: 10.1111/bpa.70068 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Pathology, 2026. Verfasst von Thomas J Auen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Craniopharyngioma, Pituitary Neoplasms. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Malignant craniopharyngiomas, de novo or via malignant transformation, are exceedingly rare with a dismal prognosis and unclear treatment standards. Little is known about the factors involved in their pathogenesis. A natural language search, performed in our institutional CoPath system, identified 65 adamantinomatous craniopharyngiomas from 56 patients (25 males, 31 females; median age at initial diagnosis = 22 years). Among those, a unique case of malignant craniopharyngioma was identified in a 36‐year‐old male initially diagnosed with a benign adamantinomatous craniopharyngioma 16 years prior. A literature review identified 44 cases of malignant craniopharyngiomas (current case included) with a median age of 28 years and a median overall survival of 6 months, independent of sex, age, histologic variant, tumor size, or radiation therapy. Eighteen (41%) malignant craniopharyngiomas occurred in patients without a history of radiation, suggesting mechanisms other than radiation contribute to their pathogenesis. Since BRCA1‐Associated Protein 1 (BAP1) and TP53 mutations have recently been reported in a case of malignant craniopharyngioma, we assessed these genes in the current case. Next‐generation sequencing identified variants in BAP1 (c.1850delGinsCA;p.R617fs), TP53 (c.428delT;p.V143fs), and CTNNB1 (c.110C>T;p.S37F). In conclusion, our results demonstrate that malignant craniopharyngioma tends to occur in young adults with a median overall survival of only 6 months. The current case is the second reported to harbor BAP1 and TP53 mutations by sequencing. BAP1 and TP53 mutations may play an important role in the pathogenesis of malignant craniopharyngioma and may offer potential targets for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Neuroscience, Columbia University, New York, New York, USA.
- Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID-Profile: Thomas J Auen, Jie Chen
Zitieren
APA
Auen, T. J., Zhang, I. W., Zhang, W., Burr, J. M., Carda, M. L., Wisecarver, J. L., Shonka, N., Cox, J. L., Cathcart, S. J., Cushman-Vokoun, A., & Chen, J. (2026). Malignant craniopharyngiomas: Institutional experience and literature review. Brain Pathology. https://doi.org/10.1111/bpa.70068
Vancouver
Auen TJ, Zhang IW, Zhang W, Burr JM, Carda ML, Wisecarver JL, et al. Malignant craniopharyngiomas: Institutional experience and literature review. Brain Pathology. 2026. doi:10.1111/bpa.70068
BibTeX
@article{Auen2026,
author = {Auen, Thomas J and Zhang, Isabella W and Zhang, Weiwei and Burr, Jordan M and Carda, Matthew L and Wisecarver, James L and Shonka, Nicole and Cox, Jesse L and Cathcart, Sahara J and Cushman-Vokoun, Allison and Chen, Jie},
title = {Malignant craniopharyngiomas: Institutional experience and literature review},
journal = {Brain Pathology},
year = {2026},
doi = {10.1111/bpa.70068}
}
EUVIMED